Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P3 and IGF2-P4 regulatory sequences

International Journal of Clinical and Experimental Medicine

Volumn 4, Issue 2, 2011, Pages 91-102

  Amit, Doron ^a   Tamir, Sagi ^a   Birman, Tatiana ^a   Gofrit, Ofer N ^b   Hochberg, Abraham ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Bladder cancer cells; Cancer; IGF2; Targeted cancer therapy

Indexed keywords

DIPHTHERIA TOXIN; LUCIFERASE; PLASMID VECTOR; POLYETHYLENEIMINE; POLYMER; SOMATOMEDIN B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; EXPRESSION VECTOR; FEMALE; GENE CONSTRUCT; GENE DELIVERY SYSTEM; GENOMIC IN SITU HYBRIDIZATION; HETEROTROPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROMOTER REGION; REGULATORY SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSITIONAL CELL CARCINOMA; TUMOR VOLUME;

ANIMALIA; MUS;

EID: 79958025545     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Marston LW, Zbar, B., Leach, F., Cordon-Cardo, C., and Issacs, W. Cancer of the genitourinary system. In Cancer: Principles & practice of oncology, V.T.DeVita, S.Hellman, and S.A.Rosenberg, eds. (Philadelppia: Lippincott Williams & Wilkins), pp. 1343-1489. 2001;
2. Matouk IJ, DeGroot N, Mezan S, Ayesh S, Abulail R, Hochberg A and Galun E. The H19 noncoding RNA is essential for human tumor growth. PLoS ONE 2007; 2: e845.
3. Matouk IJ, Mezan S, Mizrahi A, Ohana P, Abu-Lail R, Fellig Y, Degroot N, Galun E and Hochberg A. The oncofetal H19 RNA connection: hypoxia, p53 and cancer. Biochim Biophys Acta 2010; 1803: 443-451.
4. Yao X, Hu JF, Daniels M, Shiran H, Zhou X, Yan H, Lu H, Zeng Z, Wang Q, Li T and Hoffman AR. A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J Clin Invest 2003; 111: 265-273.
5. Ariel I, Lustig O, Schneider T, Pizov G, Sappir M, De-Groot N and Hochberg A. The imprinted H19 gene as a tumor marker in bladder carcinoma. Urology 1995; 45: 335-338.
6. Ariel I, Miao HQ, Ji XR, Schneider T, Roll D, de Groot N, Hochberg A and Ayesh S. Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinoma. Mol Pathol 1998; 51: 21-25.
7. Ayesh B, Matouk I, Ohana P, Sughayer MA, Birman T, Ayesh S, Schneider T, de Groot N and Hochberg A. Inhibition of tumor growth by DT-A expressed under the control of IGF2 P3 and P4 promoter sequences. Mol Ther 2003; 7: 535-541.
8. Engstrom W, Shokrai A, Otte K, Granerus M, Gessbo A, Bierke P, Madej A, Sjolund M and Ward A. Transcriptional regulation and biological significance of the insulin like growth factor II gene. Cell Prolif 1998; 31: 173-189.
9. Holthuizen PE, Cleutjens CB, Veenstra GJ, van der Lee FM, Koonen-Reemst AM and Sussenbach JS. Differential expression of the human, mouse and rat IGF-II genes. Regul Pept 1993; 48: 77-89.
10. de Pagter-Holthuizen P, Jansen M, van der Kammen RA, van Schaik FM and Sussenbach JS. Differential expression of the human insulinlike growth factor II gene. Characterization of the IGF-II mRNAs and an mRNA encoding a putative IGF-II-associated protein. Biochim Biophys Acta 1988; 950: 282-295.
11. Holthuizen P, van der Lee FM, Ikejiri K, Yamamoto M and Sussenbach JS. Identification and initial characterization of a fourth leader exon and promoter of the human IGF-II gene. Biochim Biophys Acta 1990; 1087: 341-343.
12. Ekstrom TJ, Cui H, Li X and Ohlsson R. Promoter -specific IGF2 imprinting status and its plasticity during human liver development. Development 1995; 121: 309-316.
13. Giannoukakis N, Deal C, Paquette J, Goodyer CG and Polychronakos C. Parental genomic imprinting of the human IGF2 gene. Nat Genet 1993; 4: 98-101.
14. Ohlsson R and Franklin G. Normal development and neoplasia: the imprinting connection. Int J Dev Biol 1995; 39: 869-876.
15. Morison IM and Reeve AE. Insulin-like growth factor 2 and overgrowth: molecular biology and clinical implications. Mol Med Today 1998; 4: 110-115.
16. Wu HK, Squire JA, Catzavelos CG and Weksberg R. Relaxation of imprinting of human insulinlike growth factor II gene, IGF2, in sporadic breast carcinomas. Biochem Biophys Res Commun 1997; 235: 123-129.
17. Bae SK, Bae MH, Ahn MY, Son MJ, Lee YM, Bae MK, Lee OH, Park BC and Kim KW. Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia. Cancer Res 1999; 59: 5989-5994.
18. Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Puopolo, M, Schwartz, P and Yu, H. Promoterspecific transcription of insulin-like growth factor- II in epithelial ovarian cancer. Gynecol Oncol 2006; 103: 990-995.
19. Mineo R, Fichera E, Liang SJ and Fujita- Yamaguchi Y. Promoter usage for insulin-like growth factor-II in cancerous and benign human breast, prostate, and bladder tissues, and confirmation of a 10th exon. Biochem Biophys Res Commun 2000; 268: 886-892.
20. Sohda T, Yun K, Iwata K, Soejima H and Okumura M. Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level. Lab Invest 1996; 75: 307-311.
21. Ohana P, Gofrit O, Ayesh S, Al-Sahref W, Mizrahi A, Birman T, Schneider T, Matouk I, deGroot N, Tavdy E, Sidi A and Hochberg A. Regulatory sequences of the H19 gene in DNA therapy of bladder cancer. Gene Ther. & Mol. Biol. 2004; 8: 181-192.
22. Shapiro A, Kelley DR, Oakley DM, Catalona WJ and Ratliff TL. Technical factors affecting the reproducibility of intravesical mouse bladder tumor implantation during therapy with Bacillus Calmette-Guerin. Cancer Res 1984; 44: 3051-3054.
23. Maxwell IH, Glode LM and Maxwell F. Expression of diphtheria toxin A-chain in mature Bcells: a potential approach to therapy of Blymphoid malignancy. Leuk Lymphoma 1992; 7: 457-462.
24. Fichera E, Liang S, Xu Z, Guo N, Mineo R and Fujita-Yamaguchi Y. A quantitative reverse transcription and polymerase chain reaction assay for human IGF-II allows direct comparison of IGF-II mRNA levels in cancerous breast, bladder, and prostate tissues. Growth Horm IGF Res 2000; 10: 61-70.
25. Li SL, Goko H, Xu ZD, Kimura G, Sun Y, Kawachi MH, Wilson TG, Wilczynski S and Fujita- Yamaguchi Y. Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder, and paraganglioma tumors. Cell Tissue Res 1998; 291: 469-479.
26. Kawamoto K, Onodera H, Kan S, Kondo S and Imamura M. Possible paracrine mechanism of insulin-like growth factor-2 in the development of liver metastases from colorectal carcinoma. Cancer 1999; 85: 18-25.
27. Pavelic K, Bukovic D and Pavelic J. The role of insulin-like growth factor 2 and its receptors in human tumors. Mol Med 2002; 8: 771-780